Phase 1: the revolution is ongoing!
A revolution is ongoing, which has already changed and will continue to change the role of phase 1 studies in oncology drug development.
Registration for TAT 2017 is open. Register now and take advantage of attractive early-bird rates!
Abstract submission for TAT 2017 is open. Submit your abstract before the deadline of January 6 and compete for one of the Best-Poster Awards!
Exhibitor & Support Opportunities
Act now to identify the best strategies at TAT 2017 to ensure maximum results for your company in this dynamic marketplace.
TAT 2016 report
A brief report of TAT 2016 is online now. Over the three days of the conference, 45 oral presentations covered 23 unique new drugs or drug classes in early-phase clinical trials at the time of the conference.